Evidence map›Paper›PMID 37214588›Full record

ArticleInternational journal of molecular epidemiology and genetics2023

Down-regulation of

Mohammad Abbasi-Kolli, Shirin Shahbazi, Loabat Geranpayeh

Open access · greenAbstract read
In one paragraph

Article in International journal of molecular epidemiology and genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mohammad Abbasi-KolliDepartment of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University Tehran, Iran.
Shirin ShahbaziDepartment of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University Tehran, Iran.
Loabat GeranpayehDepartment of Surgery, Sina Hospital, Tehran University of Medical Sciences Tehran, Iran.
Tarbiat Modares University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionmiR-132-3p acts in normal breast development and its downregulation has been documented in breast cancer. One of the targets of miR-132-3p is

methodsThe study was carried out on tissues obtained from female patients with primary breast cancer. Tumor samples were classified using clinical and pathological data. Following RNA extraction and cDNA synthesis, relative gene expressions in tumors were compared to non-cancerous adjacent tissues. The link between

resultsOur findings revealed a significant decrease in miR-132 and

conclusionThe reduction of miR-132 and

Indexed as

breast cancergene expressionmiRNA-132RB1

Identifiers

PMID37214588
PMCPMC10195390
OpenAlexW4377564654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.